Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Eli Lilly (LLY-0.87%) brought in $19.8 billion in revenue in the first quarter of 2026, and most of it can be traced back to ...

Quick ReadLilly acquires Atai Beckley for $2.8 billion, betting on a DMT nasal spray for treatment-resistant depression with ...

ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best psychedelic stocks on our list. TheFly reported on July 7 ...

The ATAI deal is a clear signal Lilly will fund and scale psychedelic mental-health assets, not just dabble. LLY’s cash ...

Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...

Eli Lilly has agreed to acquire psychedelic drugmaker AtaiBeckley for $6.75 per share in upfront cash, valuing the deal at ...

AtaiBeckley N.V. (NASDAQ:ATAI) is one of the 10 best stocks under $10 that could triple. On June 25, AtaiBeckley N.V. (NASDAQ:ATAI) shared that the company will be included in the Russell indices ...

atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health The Fund aims to help ...